# An Open-Label, Long-Term Extension Study to Evaluate the Safety and Tolerability Deflazacort

> **NCT02295748** · PHASE1 · COMPLETED · sponsor: **PTC Therapeutics** · enrollment: 24 (actual)

## Conditions studied

- Duchenne Muscular Dystrophy

## Interventions

- **DRUG:** Deflazacort

## Key facts

- **NCT ID:** NCT02295748
- **Lead sponsor:** PTC Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2017-08-24
- **Final completion:** 2017-08-24
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2017-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02295748

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02295748, "An Open-Label, Long-Term Extension Study to Evaluate the Safety and Tolerability Deflazacort". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT02295748. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*